Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 6, 1996, Pages 569-573

  Fleming, Gini F ^a,b   Vokes, Everett E ^a,b   Buse, John B ^b,c   Mick, Rosemarie ^a,b   Dushay, Jody ^b   Levitan, Denise ^a   Dolan, M Eileen ^a,b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 Fluorouracil; Diabetes mellitus; Dihydropyrimidine dehydrogenase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; INSULIN; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; BLOOD; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENDER; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RACE; VOLUNTEER;

ADULT; AGED; ANIMALS; BODY MASS INDEX; DIABETES MELLITUS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OXIDOREDUCTASES;

EID: 0029983740     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050430     Document Type: Article

References (24)

1. Au JL-S, Rustum YM, Ledesma EJ, Mittelman A, Creaven PJ (1982) Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal cancer. Cancer Res 42:2930-2937
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
3. Bray GA (1992) An approach to the classification and evaluation of obesity. In: Bjorntop PJ, Brodoff BN (eds) Obesitsy. J.B. Lippincott Co, Philadelphia, pp 294-308
4. Daher GC, Harris BE, Willard EM, Diasio RB (1991) Biochemical basis for circadian-dependent metabolism of fluoropyrimidines. In: Hrushesky WJM, Langer R, Theeuwes F (eds) Temporal control of drug delivery. New York Academy of Sciences, New York, pp 350-361
5. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248-2253
6. Fleming R, Milano GA, Gaspard MH, Bargnoux PJ, Thyss A, Plagne R, Renee N, Schneider M, Demard F (1993) Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 29:740-744
7. Fleming RA, Milano G, Thyss A, Etienne M-C, Renee N, Schneider M, Demard F (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899-2902
8. Goldberg JA, Kerr DJ, Wilmott N, McKillop JH, McArdle CS (1988) Pharmacokinetics and pharmacodynamics of loco-regional 5-fluorouracil (5-FU) in advanced colorectal liver metastases. Br J Cancer 57:186-189
9. Harris BE, Song R, Soong S-j, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201
10. Harris BE, Carpenter JT, Diasio RB (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer 68:499-501
11. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206
12. Houyau P, Gay C, Chatelut E, Canal P, Roche H, Milano G (1993) Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst 85:1602-1603
13. Juan D, Molitch ME, Johnson MK, Carlson RF, Antal EJ (1990) Unaltered drug metabolizing enzyme systems in type II diabetes mellitus before and during glyburide therapy. J Clin Pharmacol 30:943-947
14. Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433-5438
15. Lyss AP, Lilenbaum RC, Harris BE, Diasio RB (1993) Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 11:239-240
16. Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renee N, Schneider M, Demard F (1992) Influence of sex and age on fluorouracil clearance. J Clin Oncol 10:1171-1175
17. Santini J, Milano G, Thyss A, Renee N. Viens P, Ayela P, Schneider M, Demard F (1989) 5-FU therapeutic monitoring with dose adjustment leads to improved therapeutic index in head and neck cancer. Br J Cancer 59:287-290
18. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Cancer 75: 11
19. Thyss A, Milano G, Renee N, Vallicioni J, Schneider M, Demard F (1986) Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16:64-66
20. Trump DL, Egorin MJ, Forrest A, Willson JKV, Remick S, Tutsch KD (1991) Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 9:2027-2035
21. Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML, Mirkin BL (1985) Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313:245-249
22. Tuchman M, Roemling RV, Hrushesky WAM, Sothern RB, O'Dea RF (1989) Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells. Enzyme 42:14-24
23. Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Kozloff M, Hamasaki V, Weichselbaum RR, Panje WR, Wenig B, Berezin F (1993) Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 11:360-368
24. Zhang R, Lu Z, Liu T, Soong S-j, Diasio RB (1993) Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res 53:2816-2822